Summary
IDEXX Laboratories, Inc. (IDXX) presented its 2010 annual report on Form 10-K, highlighting a year of robust revenue growth driven primarily by its Companion Animal Group (CAG) segment. The company's diversified product and service offerings, including diagnostic and information technology solutions for veterinary practices, water testing, and livestock and poultry diagnostics, demonstrated resilience. IDEXX continued to invest in research and development, launching new products like the ProCyte Dx™ hematology analyzer and focusing on enhancing its integrated diagnostic solutions. The company also managed supply chain dependencies and faced competitive pressures, while navigating an evolving economic landscape. The report indicates a strong operational performance with a focus on innovation and market expansion.
Financial Highlights
50 data points| Revenue | $1.10B |
| Cost of Revenue | $524.77M |
| Gross Profit | $578.62M |
| R&D Expenses | $68.60M |
| Operating Income | $203.88M |
| Interest Expense | $2.42M |
| Net Income | $141.28M |
| EPS (Basic) | $1.23 |
| EPS (Diluted) | $1.19 |
| Shares Outstanding (Basic) | 115.43M |
| Shares Outstanding (Diluted) | 119.12M |
Key Highlights
- 1Total revenue grew by 7.0% to $1.103 billion in 2010, with the Companion Animal Group (CAG) being the primary driver, showing 7.4% revenue growth.
- 2The company launched its next-generation hematology analyzer, the ProCyte Dx™, in the third quarter of 2010, and saw increased sales of its Catalyst Dx® chemistry analyzer.
- 3Reference laboratory diagnostic and consulting services within CAG experienced a significant 10.5% revenue increase, indicating strong demand for outsourced diagnostic solutions.
- 4Practice information management systems and digital radiography within CAG saw robust growth of 15.6%, reflecting market adoption of digital imaging and software solutions.
- 5Gross profit margin improved to 52.4% from 51.0% in the prior year, driven by operational efficiencies in manufacturing and reference laboratories.
- 6IDEXX reported strong operating cash flow of $178.8 million, demonstrating effective cash generation from its ongoing business activities.
- 7The company actively repurchased its own shares, with $143.1 million spent on share repurchases in 2010, underscoring a commitment to returning value to shareholders and offsetting dilution.